Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Ryan Baker

CFO

Cyrus Chan

Associate

Kan Chen

Partner

Liwen Chen

Associate

Nan Chen

Principal

David Chu

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Associate

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho Ph.D

Venture Partner

William Hu

Managing Partner

Duane Kuang

Founding Managing Partner

Nisa Leung

Managing Partner

Lisa Li

Investor

Dingzheng Li

Vice President

Jing Liu

Associate

Chang Liu

Associate

Bin Liu

Associate

Biao Lu

Associate

Shuo Mao

Principal

Will Mcconnell

Principal

Mark McDade

Co-Founder and Managing Partner

Gary Rieschel

Founder and Managing Partner

Motao Sun

Associate

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Rachel Wang

Venture Partner

Xin Wang

Investor

James Wang

Venture Partner

Gillian Xu

RMB funds CFO

Kuantai Yeh

Partner

Peter (Ming) Yin

Principal, Cleantech

Janet Yu Ph.D

Partner

Liang Yuyu

Managing Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Managing Partner

Zhiyuan Zhou

Investor

Zhifeng Zhou

Managing Partner

Yiqing Zhu

Associate

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

Past deals in Generation Z

Zhenge Biotech

Series C in 2022
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Shanzhen

Series D in 2021
Shanzhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups and personalized health management plans, alongside insurance options. Additionally, Shanzhen offers a range of medical examination services and data finance products aimed at tackling the challenges posed by an aging population and the rising incidence of chronic diseases. By prioritizing the well-being of elderly patients, Shanzhen aims to enhance their quality of life, enabling them to lead happier and healthier lives.

Zeen Health

Venture Round in 2021
Zeen Health is a digital therapeutics company that provides mental health services. Zeen Health was founded in 2019 and was headquartered in Shenzhen, China.

Genlight

Series B in 2021
Genlight is a company based in Hangzhou, China, that specializes in developing advanced treatment solutions for epilepsy and other neurological disorders. The organization focuses on innovative technologies in the field of brain science and neurosurgery, creating laser medical equipment designed to improve patient outcomes. Genlight's offerings include brain-computer control technology, deep brain nerve stimulation with full-cranial implantation, brain computer chips, and a minimally invasive surgery system guided by magnetic resonance. These high-tech solutions aim to provide patients with effective and cutting-edge surgical options for neurological conditions.

Genevide

Angel Round in 2021
Genevide is a biotech company founded in 2019 and based in Suzhou, Jiangsu, China, focusing on gene research and development. The company has developed a molecular enzyme cycle screening platform designed to address challenges in nucleic acid detection. Its key technologies include enzyme-mediated one-step sample processing and enzyme-mediated double exponential amplification, which facilitate efficient nucleic acid detection for researchers. Genevide aims to provide innovative solutions that make nucleic acid detection more accessible and effective.

Zion Pharma

Series B in 2021
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Zhenge Biotech

Series B in 2021
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

ZEGOCLOUD

Venture Round in 2020
Shenzhen Zego Technology Co., Ltd. is a company based in Shenzhen, China, that specializes in real-time cloud streaming services for audio and video communications. Founded in 2015, Zego offers a comprehensive platform that supports various functionalities, including one-to-one video calls, live broadcasting, and multi-party video conferencing. The platform also provides services for real-time audio streaming, voice chatrooms, and recording and archiving of events such as bank account openings and interviews. Zego targets enterprise and mobile application developers, focusing on delivering stable and high-quality voice and video services across diverse sectors, including social media, online education, and telemedicine. Additionally, the company provides a software development kit (SDK) to facilitate the integration of its services into other applications.

Zion Pharma

Series A in 2020
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Berry Genomics

Post in 2020
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.

Genius

Series B in 2019
Genius was founded in February 2017 to focus on the field of K12 artificial intelligence education.

Shanzhen

Series D in 2019
Shanzhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups and personalized health management plans, alongside insurance options. Additionally, Shanzhen offers a range of medical examination services and data finance products aimed at tackling the challenges posed by an aging population and the rising incidence of chronic diseases. By prioritizing the well-being of elderly patients, Shanzhen aims to enhance their quality of life, enabling them to lead happier and healthier lives.

ZD Medical

Series A in 2019
ZD Medical is a medical device company that specializes in the development of innovative optical coherence tomography angiography devices. The company focuses on advancing medical imaging technology to assist healthcare professionals in identifying internal patient symptoms. By concentrating on venous medical imaging and optical imaging technology, ZD Medical aims to enhance the capabilities of healthcare providers, ultimately improving patient treatment outcomes.

Emergen

Series B in 2019
Zhejiang Zhichang Group is a cluster of robots and intelligent manufacturing enterprises founded by Dr. Gan Middle School, the first batch of national “Thousand Talents Program” experts. It has two independent core technologies: distributed intelligent robot controller and HCPS intelligent intellectual network. Three single-arm robots and smart factory eco-networks are three high-end intelligent manufacturing business areas. Committed to the development of robotic products with independent intellectual property rights, breaking the monopoly of foreign brands in the field of key components of robots, and truly realizing the national dream of "intellectual creation".

Zion Pharma

Series A in 2019
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Genor BioPharma

Venture Round in 2018
Genor BioPharma Co., Ltd. is a biopharmaceutical company based in Shanghai, China, established in 2007. The company specializes in the development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion protein drugs, focusing on oncology, autoimmune diseases, and metabolic conditions. Genor BioPharma is actively advancing a diverse pipeline of over ten products, with ten candidates currently in clinical development. Its key drug candidates include GB491, an oral CDK4/6 inhibitor, GB221, a novel HER2 mAb, and geptanolimab, among others. The company aims to address significant unmet medical needs in its therapeutic areas. Genor has also formed a strategic collaboration with Ascentage Pharma to enhance its research and development capabilities.

ZEGOCLOUD

Series B in 2018
Shenzhen Zego Technology Co., Ltd. is a company based in Shenzhen, China, that specializes in real-time cloud streaming services for audio and video communications. Founded in 2015, Zego offers a comprehensive platform that supports various functionalities, including one-to-one video calls, live broadcasting, and multi-party video conferencing. The platform also provides services for real-time audio streaming, voice chatrooms, and recording and archiving of events such as bank account openings and interviews. Zego targets enterprise and mobile application developers, focusing on delivering stable and high-quality voice and video services across diverse sectors, including social media, online education, and telemedicine. Additionally, the company provides a software development kit (SDK) to facilitate the integration of its services into other applications.

ZD Medical

Series A in 2018
ZD Medical is a medical device company that specializes in the development of innovative optical coherence tomography angiography devices. The company focuses on advancing medical imaging technology to assist healthcare professionals in identifying internal patient symptoms. By concentrating on venous medical imaging and optical imaging technology, ZD Medical aims to enhance the capabilities of healthcare providers, ultimately improving patient treatment outcomes.

Berry Genomics

Funding Round in 2018
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.

Berry Genomics

Funding Round in 2017
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.

Zhihu

Series D in 2017
Zhihu (知乎) is a Chinese socialized website for questions and answers. It differs from traditional online question and answer forums by enabling users to obtain information through questions that provoke the opinions and views from answerers as individuals. The number of registered users on Zhihu has surpassed 300,000 by the end of January 2012. Zhihu was founded in 2011.

Zhihu

Series C in 2015
Zhihu (知乎) is a Chinese socialized website for questions and answers. It differs from traditional online question and answer forums by enabling users to obtain information through questions that provoke the opinions and views from answerers as individuals. The number of registered users on Zhihu has surpassed 300,000 by the end of January 2012. Zhihu was founded in 2011.

Zhihu

Series B in 2014
Zhihu (知乎) is a Chinese socialized website for questions and answers. It differs from traditional online question and answer forums by enabling users to obtain information through questions that provoke the opinions and views from answerers as individuals. The number of registered users on Zhihu has surpassed 300,000 by the end of January 2012. Zhihu was founded in 2011.

Berry Genomics

Series B in 2013
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.

Zhihu

Series A in 2011
Zhihu (知乎) is a Chinese socialized website for questions and answers. It differs from traditional online question and answer forums by enabling users to obtain information through questions that provoke the opinions and views from answerers as individuals. The number of registered users on Zhihu has surpassed 300,000 by the end of January 2012. Zhihu was founded in 2011.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.